Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Benny JohnsonCara L HaymakerEdwin R ParraLuisa Maren Solis SotoXuemei WangJane V ThomasArvind DasariVan K MorrisKanwal RaghavEduardo VilarBryan K KeeCathy EngChristine M ParseghianRobert A WolffYounghee LeeDaniele LorenziniCaddie Laberiano-FernandezAnuj VermaWenhua LangIgnacio I WistubaAndrew FutrealScott KopetzMichael J Overman

Published in: Journal for immunotherapy of cancer (2022)

NCT03428126.

Keyphrases

phase ii study
metastatic colorectal cancer
open label
locally advanced
placebo controlled
rectal cancer
squamous cell carcinoma
clinical trial
radiation therapy
randomized controlled trial